RLMD Stock Forecast: Relmada Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Relmada Therapeutics, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 55 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Relmada Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (77): Analysts have, on balance, been raising their forecasts.
Volatility (24): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RLMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RLMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 June 2026 | HC Wainwright & Co. | Initiates | Buy | $12 |
| 24 Mar 2026 | Piper Sandler | Initiates | Overweight | — |
| 20 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 2 Mar 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 23 Jan 2026 | Leerink Partners | Upgrade | Outperform | — |
| 22 Dec 2025 | Jefferies | Initiates | Buy | — |
| 19 Nov 2025 | Mizuho | Upgrade | Outperform | — |
| 5 Dec 2024 | Mizuho | Downgrade | Neutral | — |
| 4 Dec 2024 | Leerink Partners | Downgrade | Market Perform | — |
| 17 Sept 2024 | Jefferies | Upgrade | Buy | $3.50 → $13 |
| 5 June 2024 | Goldman Sachs | Downgrade | Sell | — |
| 15 June 2023 | Mizuho | Reiterates | Buy | — |
| 23 Jan 2023 | SVB Leerink | Maintains | Outperform | — |
| 14 Oct 2022 | Goldman Sachs | Downgrade | Neutral | — |
| 14 Oct 2022 | Guggenheim | Downgrade | Neutral | — |
| 13 Oct 2022 | Oppenheimer | Downgrade | Perform | — |
| 23 Sept 2022 | Goldman Sachs | Maintains | Buy | — |
| 6 Sept 2022 | Guggenheim | Maintains | Buy | — |
| 9 May 2022 | Oppenheimer | Maintains | Outperform | — |
| 24 Mar 2022 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RLMD.
This page is one stock. Monday covers all of them.
RLMD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RLMD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Relmada Therapeutics, Inc. returned −39.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RLMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.4×
- EV / EBITDA
- —
Cheaper than 56% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −64.7%
- Return on assets
- −36.9%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Relmada Therapeutics, Inc. has a market value of $279.5M and an enterprise value of $77.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$61.9M.
Free cash flow in the twelve months to 30 June 2026: −$46.0M.
Relmada Therapeutics, Inc. employs 17 people.
Data provided by Twelve Data
RLMD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RLMD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Relmada Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RLMD
What is the RLMD stock price forecast for 2026-2027?
The median 12-month analyst price target for Relmada Therapeutics, Inc. is $11, with estimates ranging from $9 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RLMD stock a buy right now?
Of the 4 analysts covering Relmada Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relmada Therapeutics, Inc. 55 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RLMD?
As at 21 Nov 2026, Relmada Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (77 of 100).
Will RLMD stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $11, and Ticker Nerd's factor model ranks Relmada Therapeutics, Inc. 55 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RLMD stock forecast for 2030?
No analyst covering Relmada Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $12 over the next 12 months.
How has RLMD stock performed over the past year?
Relmada Therapeutics, Inc. returned -39.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Relmada Therapeutics, Inc. do?
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders. Its current pipeline centers on product candidates designed to address areas of significant unmet medical need, including NDV-01 for non-muscle invasive bladder cancer and sepranolone for neurological and compulsivity-related conditions.
About Relmada Therapeutics, Inc.
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders. Its current pipeline centers on product candidates designed to address areas of significant unmet medical need, including NDV-01 for non-muscle invasive bladder cancer and sepranolone for neurological and compulsivity-related conditions. The company also advances esmethadone, a novel NMDA receptor antagonist being evaluated for central nervous system indications such as major depressive disorder and other related disorders. Relmada Therapeutics Inc. operates as a research-driven drug developer, using targeted clinical programs to explore new treatment options across cancer, psychiatric, and neurological care. Headquartered in Coral Gables, Florida, the company remains focused on late-stage development of proprietary therapies intended to expand treatment possibilities in specialized disease areas.
CEO Dr. Sergio Traversa M.B.A., Pharm.D. · 17 employees · United States · https://www.relmada.com